| Louis Brenner |
Louis Brenner is President, Chief Executive Officer & Director at Allena Pharmaceuticals, Inc. Dr. Brenner is also on the board of Goldfinch Bio, Inc. and Lecturer at Harvard University.
He previously occupied the position of Chief Medical Officer & Senior Vice President at Idera Pharmaceuticals, Inc., Chief Medical Officer & Senior Vice President for Radius Health, Inc., Senior Director-Business Development-Renal Unit at Genzyme Corp. and Senior Vice President at AMAG Pharmaceuticals, Inc.
He received an undergraduate degree from Yale University, a doctorate from Duke University and an MBA from Harvard Business School. |
| Richard D. Katz |
Richard D. Katz is Chief Financial Officer of Allena Pharmaceuticals, Inc.
Dr. Katz previously occupied the position of Chief Financial Officer at Icagen, Inc., Chief Financial & Business Officer at Viamet Pharmaceuticals Corp. and Chief Financial & Business Officer at Viamet Pharmaceuticals, Inc. (a subsidiary of Viamet Pharmaceuticals Corp.), CFO, Vice President & Investor Relations Contact at Argos Therapeutics, Inc., Chief Financial Officer of Liquidia Corp. and Chief Financial Officer for Liquidia Technologies, Inc. (a subsidiary of Liquidia Corp.), CFO, Executive VP-Finance & Corporate Development at Neusentis, Inc. and Vice President for Goldman Sachs & Co. LLC.
He received an undergraduate degree from Harvard University, a doctorate from Stanford University School of Medicine and an MBA from Harvard Business School. |
| Alexey L. Margolin |
Alexey L. Margolin founded Allena Pharmaceuticals, Inc., Alnara Pharmaceuticals, Inc. and Alcresta Therapeutics, Inc. Presently, Dr. Margolin occupies the position of Chairman at Allena Pharmaceuticals, Inc. Dr. Margolin is also on the board of Alcresta Therapeutics, Inc. (former Chairman).
In the past Dr. Margolin held the position of Chief Scientific Officer & Senior VP-Research at Altus Pharmaceuticals, Inc. and President & Chief Executive Officer for Alnara Pharmaceuticals, Inc.
He received a doctorate and a graduate degree from Moscow University. |
| David J. Clark |
David J. Clark is a businessperson who has been the head of 7 different companies and holds the position of President at Pasteur Merieux MSD Ltd. and Chief Medical Officer for Allena Pharmaceuticals, Inc.
In his past career he was Chairman for Mersana Therapeutics, Inc., President & Chief Executive Officer of Neose Technologies, Inc., Chief Medical Officer for Aldeyra Therapeutics, Inc., Chief Medical Officer at NormOxys, Inc., Principal at Pfizer Inc. and President & Chief Executive Officer for Oncology.com, Inc. (a subsidiary of Pfizer Inc.), Principal at GSK Plc and Principal at SmithKline Beecham Ltd. (a subsidiary of GSK Plc), Chairman of TOLMAR Therapeutics, Inc., Executive Chairman of LigoCyte Pharmaceuticals, Inc., President & Chief Executive Officer of MedImmune Vaccines, Inc., Chief Medical Officer of Wilson Therapeutics AB and Senior Vice President-Translational Medicine at VTVX Holdings I LLC.
Dr. Clark received a doctorate from The University of Edinburgh. |
| Geoffrey A. Swire |
Geoffrey A. Swire is COO & Senior Vice President-Corporate Development at Allena Pharmaceuticals, Inc.
In his past career he was Head-Business Development & Alliance Management at Radius Health, Inc. and Head-Program & Portfolio Management at Genzyme Corp.
Geoffrey A. Swire received an undergraduate degree from Dartmouth College and a graduate degree from Harvard University. |
| Allene M. Diaz |
Allene M. Diaz is Member of Healthcare Businesswomens Association and Senior Consultant at Xilio Therapeutics, Inc. and on the board of 5 other companies.
In the past she occupied the position of Senior Vice President-Managed Markets at Merck KGaA and Senior Vice President-Managed Markets at EMD Serono, Inc. (a subsidiary of Merck KGaA), SVP-Research & Development Portfolio Management at GSK Plc and SVP-Commercial Development & Program Strategy at Tesaro, Inc. (a subsidiary of GSK Plc) and Principal at CancerVax Corp.
She received an undergraduate degree from Florida State University. |
| Mark J. Fitzpatrick |
Mark J. Fitzpatrick holds the position of Chief Executive Officer & Director at Versantis AG. Mr. Fitzpatrick is also on the board of Allena Pharmaceuticals, Inc.
In the past he occupied the position of Chief Financial Officer at RenaMed Biologics, Inc., Chief Financial Officer & Senior Vice President for WorldStreet Corp., Principal at Repligen Corp., President & Chief Financial Officer at Chiasma, Inc., Chief Financial Officer & Vice President at Diacrin, Inc. (Delaware), Chief Financial Officer of Dynogen Pharmaceuticals, Inc., Chief Financial Officer & Vice President for Proteon Therapeutics, Inc., Chief Financial Officer for Aegerion Pharmaceuticals, Inc. and Senior Auditor at Arthur Andersen LLP.
Mark J. Fitzpatrick received an undergraduate degree from Boston College. |
| Gino Santini |
Gino Santini is Advisor at Prime Movers Lab LLC. He is also on the board of 8 other companies.
Mr. Santini previously was SVP-Corporate Strategy & Business Devlopment at Eli Lilly & Co. and General Manager at Eli Lilly y CIA de México SA de CV (a subsidiary of Eli Lilly & Co.), Chairman at AMAG Pharmaceuticals, Inc., Chairman of National Pharmaceutical Council and Chairman for Noble of Indiana.
He received an undergraduate degree from Alma Mater Studiorum - Università di Bologna, an MBA from the University of Rochester Simon Business School and an undergraduate degree from Università di Bologna Buenos Aires. |
| Ann Calby Miller |
Ann Calby Miller is on the board of Inovio Pharmaceuticals, Inc. and Allena Pharmaceuticals, Inc.
Dr. Miller previously held the position of Senior Vice President-Pharmaceutical Services at Eisai Co., Ltd., Executive Director-Global Marketing at Amgen, Inc. and Vice President-Marketing & Global Marketing at Sanofi SA.
Dr. Miller received an undergraduate degree from Duke University and a doctorate from Duke University School of Medicine. |
